These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32662350)

  • 1. Ticagrelor is Not Superior to Clopidogrel in Patients With Acute Coronary Syndromes Undergoing PCI: A Report from Swedish Coronary Angiography and Angioplasty Registry.
    Völz S; Petursson P; Odenstedt J; Ioanes D; Haraldsson I; Angerås O; Dworeck C; Hirlekar G; Myredal A; Albertsson P; Råmunddal T; Redfors B; Omerovic E
    J Am Heart Assoc; 2020 Jul; 9(14):e015990. PubMed ID: 32662350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.
    Redfors B; Dworeck C; Haraldsson I; Angerås O; Odenstedt J; Ioanes D; Petursson P; Völz S; Albertsson P; Råmunddal T; Persson J; Koul S; Erlinge D; Omerovic E
    Eur Heart J; 2019 Apr; 40(15):1202-1210. PubMed ID: 30851037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
    Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
    JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial.
    Welsh RC; Sidhu RS; Cairns JA; Lavi S; Kedev S; Moreno R; Cantor WJ; Stankovic G; Meeks B; Yuan F; Džavík V; Jolly SS
    Can J Cardiol; 2019 Oct; 35(10):1377-1385. PubMed ID: 31492492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of P2Y
    Gosling R; Yazdani M; Parviz Y; Hall IR; Grech ED; Gunn JP; Storey RF; Iqbal J
    Platelets; 2017 Dec; 28(8):767-773. PubMed ID: 28267384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y
    Choe JC; Cha KS; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH;
    Int J Cardiol; 2019 Jan; 274():21-26. PubMed ID: 30224257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
    Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
    Damman P; Varenhorst C; Koul S; Eriksson P; Erlinge D; Lagerqvist B; James SK
    Am J Cardiol; 2014 Jan; 113(1):64-9. PubMed ID: 24169009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndromes With Outcomes.
    Dworeck C; Redfors B; Angerås O; Haraldsson I; Odenstedt J; Ioanes D; Petursson P; Völz S; Persson J; Koul S; Venetsanos D; Ulvenstam A; Hofmann R; Jensen J; Albertsson P; Råmunddal T; Jeppsson A; Erlinge D; Omerovic E
    JAMA Netw Open; 2020 Oct; 3(10):e2018735. PubMed ID: 33001202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database.
    Sirker A; Kwok CS; Kontopantelis E; Johnson T; Freeman P; de Belder MA; Ludman P; Zaman A; Mamas MA
    Catheter Cardiovasc Interv; 2018 Oct; 92(4):659-665. PubMed ID: 29356278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.
    Silvain J; Lattuca B; Beygui F; Rangé G; Motovska Z; Dillinger JG; Boueri Z; Brunel P; Lhermusier T; Pouillot C; Larrieu-Ardilouze E; Boccara F; Labeque JN; Guedeney P; El Kasty M; Laredo M; Dumaine R; Ducrocq G; Collet JP; Cayla G; Blanchart K; Kala P; Vicaut E; Montalescot G;
    Lancet; 2020 Nov; 396(10264):1737-1744. PubMed ID: 33202219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
    Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis.
    Komosa A; Lesiak M; Krasiński Z; Grygier M; Siniawski A; Skorupski W; Olasińska-Wiśniewska A; Pyda M; Araszkiewicz A; Mitkowski P; Grajek S; Mularek-Kubzdela T; Hengstenberg C; Siller-Matula JM
    Thromb Haemost; 2019 Jun; 119(6):1000-1020. PubMed ID: 30919382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment With P2Y12 Inhibitors in Patients With Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the Swedish Coronary Angiography and Angioplasty Registry.
    Jurga J; Szummer KE; Lewinter C; Mellbin L; Götberg M; Zwackman S; Nilsson J; Völz S; Erlinge D; Persson J; Omerovic E; Jernberg T; Venetsanos D
    Circ Cardiovasc Interv; 2021 Nov; 14(11):e010849. PubMed ID: 34592825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Data on Potent P2Y12 Inhibition in Patients with Suspected Chronic Coronary Syndrome, Referred for Coronary Angiography.
    Träff E; Venetsanos D; Alpkvist K; Sederholm Lawesson S; Skibniewski M; Zwackman S; Alfredsson J
    Cardiology; 2022; 147(5-6):486-496. PubMed ID: 36215960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
    Gach O; Nyssen A; Pirlet C; Magne J; Oury C; Lancellotti P
    J Cardiovasc Med (Hagerstown); 2018 May; 19(5):234-239. PubMed ID: 29528868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Turgeon RD; Koshman SL; Youngson E; Har B; Wilton SB; James MT; Graham MM
    JAMA Intern Med; 2020 Mar; 180(3):420-428. PubMed ID: 31930361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Shimada YJ; Bansilal S; Wiviott SD; Becker RC; Harrington RA; Himmelmann A; Neely B; Husted S; James SK; Katus HA; Lopes RD; Steg PG; Storey RF; Wallentin L; Cannon CP;
    Am Heart J; 2016 Jul; 177():1-8. PubMed ID: 27297843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prehospital Adenosine Diphosphate Receptor Blocker Use, Culprit Artery Flow, and Mortality in STEMI: The MADDEC Study.
    Hautamäki M; Lyytikäinen LP; Eskola M; Lehtimäki T; Nikus K; Oksala N; Tynkkynen J; Hernesniemi J
    Clin Drug Investig; 2021 Jul; 41(7):605-613. PubMed ID: 34101137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
    Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.